Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ficerafusp alfa
- Development stage
- Phase 3
- Lead developer
- Bicara Therapeutics
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Ficerafusp alfa is a first-in-class, bifunctional recombinant fusion protein developed by Bicara Therapeutics. It is designed to target two clinically validated pathways in cancer—epidermal growth factor receptor (EGFR) and transforming growth factor beta (TGF-β). The molecule consists of an EGFR-directed monoclonal antibody fused with a domain that binds TGF-β, enabling it to simultaneously block EGFR-mediated tumor cell survival/proliferation and neutralize immunosuppressive TGF-β signaling within the tumor microenvironment. This dual mechanism aims to enhance anti-tumor immune responses and improve clinical outcomes in solid tumors, particularly head and neck squamous cell carcinoma (HNSCC). Ficerafusp alfa is administered intravenously and has shown promising efficacy in early-phase clinical trials when combined with pembrolizumab[1][2][4][6].
- Other names
- EGFR/TGFβ fusion monoclonal antibody
02
Targets
EGFR (Epidermal growth factor receptor)TGFB1 (Transforming growth factor Beta-1 proprotein)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on ficerafusp alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ficerafusp alfa.